PNT News and Press, POINT Biopharma Global Inc. From 09/18/23

INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and Athe...

2023-08-14 10:46:36 ET More on POINT Biopharma POINT Biopharma: Leading The Future Of Radioligand Therapy POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financ...

2023-08-14 09:44:20 ET POINT Biopharma Global press release ( NASDAQ: PNT ): Q2 GAAP EPS of -$0.24. Revenue of $4.87M. For further details see: POINT Biopharma Global GAAP EPS of -$0.24, revenue of $4.87M

Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024 Company released its first terbium-161 preclinical...

2023-08-02 01:17:40 ET Summary POINT Biopharma is a leader in radioligand therapy, specializing in the development and commercialization of targeted radioligand therapies for cancer treatment. The company reported a strong financial standing with $519.2 million in cash and investm...

2023-08-01 00:23:22 ET Summary POINT Biopharma has two therapies in Phase 3 development with fast track designation, which creates the potential for positive catalysts as early as this year. Positive results from the Phase 2 study of PNT2002 provide optimism for successful results...

GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ: PNT) (“POINT”), a company accelerating the discovery, development, ...

INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and AdvanCell, a comp...

Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555 Preclinical proof-of-concept established for synergistic interaction of immuno- a...

INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the filling of its vacant b...